
Early Recognition of AMR-An Opportunity for Improved Diagnosis of Sepsis¹



Superbugs increasingly resistant to standard of care practices POST-PANDEMIC

78% increase

in the number of hospital-onset Carbapenem-resistant Acinetobacter infections.²

32% increase

in hospital-onset **ESBL-producing Enterobacterales** infections.²

32% increase

in hospital-onset Multidrug-resistant Pseudomonas aeruginosa infections.²

Sepsis is a major cause of mortality & morbidity

Approximately 50% of sepsis cases globally occur in children under 5 years old.³



Affects 49 million people per year, kills **11 million people** per year.³

Up to **50% of sepsis** survivors suffer

from long-term physical and/or psychological effects.⁴

Accurate diagnosis decreases the burden of sepsis

MicroScan systems

U.S. spends estimated \$62B annually

on sepsis treatment most costly in-patient condition covered by Medicare.⁵

use **direct MICs** for the detection of emerging resistance, providing accurate and timely results without reliance on historical data.

Antibiotic administration decreases the likelihood of death by **7.6% per hour.**¹

Beckman Coulter is dedicated to its Microbiology Vision "Accelerating Innovation To Improve Antimicrobial Therapy Decisions For Every Patient."





- 1. Paula Rojas-Garcia et al. https://doi.org/10.3390/antibiotics11010027 –Introduction
- 2. https://www.cdc.gov/antimicrobial-resistance/media/pdfs/covid19-impact-report-508.pdf –Pages 15, 16
- 3. https://www.who.int/news-room/fact-sheets/detail/sepsis –Key Facts
- 4.https://www.sepsis.org/sepsis-basics/post-sepsis-syndrome/
- 5. Buchman TG, et al. https://DOI:10.1097/CCM.000000000004225

© 2024 Beckman Coulter, Inc. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

